glp 1 skin GLP-1RA & Inflammatory Diseases What Providers Are Noticing About

Verified documentation

People with gastroparesis are disproportionately female

L., Hendrich, S., & Birt, D

Diabetes Obes Metab 23(3):754762 Vilsbll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Semaglutide dose-dependently reduced liver enzymes, and resulted in greater NASH resolution (reduced ballooning and lobular inflammation) without worsening of fibrosis, as compared with placebo after 72 weeks of treatment

Modern advances in long-acting peptide design, biased agonism, receptor de-orphanization, and systems pharmacology fundamentally alter the riskbenefit calculus of these targets